Identification of Polo-like kinases as potential novel drug targets for influenza A virus
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of Polo-like kinases as potential novel drug targets for influenza A virus
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-08-11
DOI
10.1038/s41598-017-08942-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication
- (2017) Ahmed Diab et al. HEPATOLOGY
- Functions of Polo-Like Kinases: A Journey From Yeast To Humans
- (2016) Rajni Vaid et al. PROTEIN AND PEPTIDE LETTERS
- Polo-like kinase and its inhibitors: Ready for the match to start?
- (2015) Neil D. Palmisiano et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy
- (2015) Matthildi Valianou et al. CELL CYCLE
- Meta- and Orthogonal Integration of Influenza “OMICs” Data Defines a Role for UBR4 in Virus Budding
- (2015) Shashank Tripathi et al. Cell Host & Microbe
- Recent strategies and progress in identifying host factors involved in virus replication
- (2015) Renate König et al. CURRENT OPINION IN MICROBIOLOGY
- The Cellular Factor NXP2/MORC3 Is a Positive Regulator of Influenza Virus Multiplication
- (2015) Lorena S. Ver et al. JOURNAL OF VIROLOGY
- Dengue Virus Evolution under a Host-Targeted Antiviral
- (2015) Emily Plummer et al. JOURNAL OF VIROLOGY
- Advances in the development of influenza virus vaccines
- (2015) Florian Krammer et al. NATURE REVIEWS DRUG DISCOVERY
- Temporal SILAC-based quantitative proteomics identifies host factors involved in chikungunya virus replication
- (2015) Emmely E. Treffers et al. PROTEOMICS
- Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment
- (2015) Xiaoqi Liu Translational Oncology
- Cathepsin W Is Required for Escape of Influenza A Virus from Late Endosomes
- (2015) Thomas O. Edinger et al. mBio
- Prolidase Is Required for Early Trafficking Events during Influenza A Virus Entry
- (2014) M. O. Pohl et al. JOURNAL OF VIROLOGY
- Polo-like kinases: structural variations lead to multiple functions
- (2014) Sihem Zitouni et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Pooled RNAi screen identifies ubiquitin ligase Itch as crucial for influenza A virus release from the endosome during virus entry
- (2013) W.-C. Su et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Novel Human Influenza A(H7N9) Virus Is Naturally Adapted to Efficient Growth in Human Lung Tissue
- (2013) J. Knepper et al. mBio
- A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer
- (2012) Peter M. Ellis et al. Clinical Lung Cancer
- Newer influenza antivirals, biotherapeutics and combinations
- (2012) Frederick G. Hayden Influenza and Other Respiratory Viruses
- Influenza A Viruses Target Type II Pneumocytes in the Human Lung
- (2012) V. K. Weinheimer et al. JOURNAL OF INFECTIOUS DISEASES
- The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study
- (2012) Julie M. Vose et al. LEUKEMIA & LYMPHOMA
- Uncovering the global host cell requirements for influenza virus replication via RNAi screening
- (2011) Silke Stertz et al. MICROBES AND INFECTION
- An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors
- (2010) R.-D. Hofheinz et al. CLINICAL CANCER RESEARCH
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- (2010) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial
- (2010) Martin Sebastian et al. Journal of Thoracic Oncology
- Polo-Like Kinase 1 Is Involved in Hepatitis C Virus Replication by Hyperphosphorylating NS5A
- (2010) Y.-C. Chen et al. JOURNAL OF VIROLOGY
- Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication
- (2010) Alexander Karlas et al. NATURE
- Influenza A virus induces p53 accumulation in a biphasic pattern
- (2009) Yang Shen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Physical and Regulatory Map of Host-Influenza Interactions Reveals Pathways in H1N1 Infection
- (2009) Sagi D. Shapira et al. CELL
- The IFITM Proteins Mediate Cellular Resistance to Influenza A H1N1 Virus, West Nile Virus, and Dengue Virus
- (2009) Abraham L. Brass et al. CELL
- Matrix Protein 2 of Influenza A Virus Blocks Autophagosome Fusion with Lysosomes
- (2009) Monique Gannagé et al. Cell Host & Microbe
- Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy
- (2009) S. Ludwig JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Human host factors required for influenza virus replication
- (2009) Renate König et al. NATURE
- Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
- (2008) Klaus Mross et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now